VINCRISTINE SULFATE INJECTION SOLUTION

Страна: Канада

мова: англійська

Джерело: Health Canada

Активний інгредієнт:

VINCRISTINE SULFATE

Доступна з:

TEVA CANADA LIMITED

Код атс:

L01CA02

ІПН (Міжнародна Ім'я):

VINCRISTINE

Дозування:

1MG

Фармацевтична форма:

SOLUTION

Склад:

VINCRISTINE SULFATE 1MG

Адміністрація маршрут:

INTRAVENOUS

Одиниць в упаковці:

1/2/5ML

Тип рецепту:

Prescription

Терапевтична области:

ANTINEOPLASTIC AGENTS

Огляд продуктів:

Active ingredient group (AIG) number: 0107646001; AHFS:

Статус Авторизація:

APPROVED

Дата Авторизація:

2014-03-06

Характеристики продукта

PRODUCT MONOGRAPH
PR
VINCRISTINE SULFATE INJECTION
USP
1 mg/mL
THERAPEUTIC
CLASSIFICATION
Antineoplastic Agent
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario,
Canada M1B 2K9
Date of Revision:
October 12, 2022
CONTROL # 263864
PR
vinCRIStine SULFATE INJECTION
USP
1 mg/mL
THERAPEUTIC CLASSIFICATION
Antineoplastic Agent
___________________________________________________________________________
CAUTION: VINCRISTINE SULFATE INJECTION IS A POTENT DRUG AND
SHOULD BE USED ONLY BY PHYSICIANS EXPERIENCED WITH CANCER
CHEMOTHERAPEUTIC DRUGS. BLOOD COUNTS SHOULD BE TAKEN ONCE OR
TWICE WEEKLY. DISCONTINUE OR REDUCE THE DOSAGE UPON EVIDENCE
OF ABNORMAL DEPRESSION OF THE BONE MARROW.
THIS PREPARATION SHOULD BE ADMINISTERED BY INDIVIDUALS EXPERIENCED IN
THE ADMINISTRATION OF
VINCRISTINE SULFATE INJECTION. IT IS EXTREMELY IMPORTANT THAT THE
INTRAVENOUS NEEDLE OR CATHETER
BE PROPERLY POSITIONED BEFORE ANY VINCRISTINE IS INJECTED. LEAKAGE
INTO SURROUNDING TISSUE
DURING INTRAVENOUS ADMINISTRATION OF VINCRISTINE SULFATE INJECTION MAY
CAUSE CONSIDERABLE
IRRITATION. IF EXTRAVASATION OCCURS, THE INJECTION SHOULD BE
DISCONTINUED IMMEDIATELY, AND ANY
REMAINING PORTION OF THE DOSE SHOULD THEN BE INTRODUCE D INTO ANOTHER
VEIN. LOCAL INJECTION OF
HYALURONIDASE AND THE APPLICATION OF MODERATE HEAT TO THE AREA OF
LEAKAGE HELP DISPERSE THE
DRUG AND ARE THOUGHT TO MINIMIZE DISCOMFORT AND THE POSSIBILITY OF
CELLULITIS.
TO REDUCE THE POTENTIAL FOR FATAL MEDICATION ERRORS DUE TO INCORRECT
ROUTE OF ADMINISTRATION, VINCRISTINE
SULFATE INJECTION SHOULD BE DILUTED IN A FLEXIBLE PLASTIC CONTAINER
AND PROMINENTLY LABELLED AS INDICATED:
“
FOR INTRAVENOUS USE ONLY - FATAL IF GIVEN BY OTHER ROUTES.
”
SEE "WARNINGS" SECTION FOR THE TREATMENT OF PATIENTS INADVERTENTLY
GIVEN INTRATHECAL
VINCRISTINE SULFATE INJECTION.
ACTION AND CLINICAL PHARMACOLOGY
The
complete
mode of action of vincristine sulfate is unknown. _ In vitro _
investigations have
demonstrated that vincristine is a spindle inhibitor. This inhibition
has been linked to a reversible
bin